Labour royal commission into legalisation of drugs could lead to decriminalising heroin and cocaine

A Labour government would launch a royal commission to review the legalisation of drugs including cannabis, cocaine and heroin.

In a move that could see Britain abandon its decades-long war on drugs and adopt a public health approach, Jeremy Corbyn would launch a wide-ranging study of “all drugs legislation”.

The government could decriminalise certain substances and make others fully available for recreational or medical purposes, with Labour insisting it would be led by evidence alone.

Diane Abbott, the shadow home secretary, said: “We will establish a royal commission to review independently all drugs legislation and policy to address related issues of public health.

“There is nothing more important than preserving the life of our citizens. Our current approach to drugs is simply not doing that.”

Subscription needed to finish…

POT of gold on the south coast: British company planning to grow marijuana is plotting £100 million float that will make it largest cannabis business on the London Stock Exchange



The Last Post I have to get a plain to my next job thanks for all your likes its the only currency uk420 has lol see you next week take care all! :yep:


POT of gold on the south coast: British company planning to grow marijuana is plotting £100 million float that will make it largest cannabis business on the London Stock Exchange


A British company which has assembled a heavyweight board and is planning to grow marijuana in England is plotting a £100 million float that would make it the largest cannabis business on the London Stock Exchange.

Cannaray will become the only London-listed UK grower of cannabis next summer if it secures its licence to cultivate the plant on the south coast of England and floats on the stock market as planned.

The company, which has City big hitters on the board including a former Royal Bank of Scotland executive, has just raised £7.8 million and is now in the process of rounding up another £3.5 million of investment.

It then hopes to raise up to £30 million in a stock market float next year which could value it at more than £100 million, making it the largest London-listed cannabis company and the only one with a licence to grow cannabis in the UK.


Chief executive Scott Maguire is planning a main listing on the LSE, rather than floating on the challenger NEX Exchange, which a number of smaller players have done recently.

‘I believe that’s a recipe for failure,’ he said of listing on NEX. ‘You might as well stay private because there’s no volume or liquidity on that exchange. It would be a main board listing that would allow the company to raise the magnitude of capital necessary to become a global cannabis player.’

The cannabis grown by Cannaray will be prescribed by doctors to treat patients suffering from chronic pain, vomiting and nausea caused by chemotherapy, epilepsy and multiple sclerosis.

It is also in talks to launch its cannabis oils on supermarket shelves by February.


Cannabis-based medicines were made available by prescription through the NHS last year, prompting a number of entrepreneurs to chase London listings to cash in on the fevered enthusiasm.

Cannaray would use the money from the float to start processing the cannabis it will be growing so that it is up to medical standards and ready for patients to smoke, vape or take in the form of oils, capsules or creams.

The firm’s current investors include Newey, Britain’s biggest potted plant grower. The pair have struck a deal so that Newey will grow cannabis for Cannaray, starting with a one-acre greenhouse.

It has applied to the Home Office and is in talks with the authorities, including the police, about securing the site with the help of ex-Special Forces operatives to make it like ‘Fort Knox’, according to Maguire. 


It would be only the second greenhouse in Britain where a company grows cannabis legally to sell to patients.

British Sugar grows cannabis in Downham Market in Norfolk for GW Pharmaceuticals, which used to be listed on AIM in London but is now on Nasdaq in New York. That greenhouse, however, is much larger at around 18 hectares. In 2017, local residents complained of a smell from the site.

The exact location of the greenhouse that will grow Cannaray’s product is being kept confidential for now because of the high level of security being built around the site to protect it from being broken into. But it is known it will be close to the south coast of England.

Most start-ups looking to cash in on the hype surrounding cannabis stocks and the legalisation of medicinal cannabis are led by little-known entrepreneurs with boards made up of corporate financiers.

But Maguire, an American biotech veteran who has lived in the UK for more than 20 years, has assembled a heavyweight board and an impressive scientific advisory board. 


Cannaray’s directors include Chris Sullivan, former deputy chief executive of RBS, and Sir Nigel Knowles, former chief executive of legal giant DLA Piper, who chairs listed law firm DWF. Both are Maguire’s former golfing partners at Wentworth.

It is the first role for Sullivan since he retired from Santander last year, where he ran the corporate banking division. Previously he was RBS’s deputy chief executive and also ran the bailed-out lender’s corporate banking division.

Sullivan was accused of being ‘wilfully obtuse’ when he gave evidence to the Treasury Select Committee about the notorious Global Restructuring Group (GRG), a division of RBS which critics claim drove to the wall small firms they were supposed to be helping.

A spokesman for Cannaray said Sullivan ‘understands the potential of cannabis medicines as a future replacement for many opioid-based therapies and has a desire to make a positive impact on society.

‘He is also a keen golfer and has read how many golfers are now using CBD [cannabidiol, a cannabis extract] for anxiety and aches and pains.’

Sullivan joined the board as a non-executive director this month, but invested in the company in June. Most of the investors so far are businessmen that Maguire has rounded up.



Legalise cannabis, says Liberal Democrat candidate for London mayor



Legalise cannabis, says Liberal Democrat candidate for London mayor




Siobhan Benita says the capital should make the move to tackle youth crime


Siobhan Benita, Liberal Democrats candidate for London mayor next year, says legalising cannabis would help police tackle violent youth crime in the capital



The legalisation of cannabis should be tested in London to improve public health and stop young people being drawn into crime, a London mayoral candidate has said.

Siobhan Benita, the Lib Dem candidate for next year’s election, said the idea of legalising the drug was “no longer controversial” and the serious crime in the capital meant it was the right place for the idea to be trialled.


“Illegal drugs activity, especially in the capital, is a big part of pulling young people into serious violence,” she told the Observer. “I want to remove power from those gangs. My question would be, why haven’t we done this yet? It’s not controversial any more. We’ve got enough examples now of countries around the world and we can compare and contrast how they have done it. We now have lots more evidence on where it is working well.”


She said legalisation, which would free up police time, had been supported by prominent former police officers. “This has been a Lib Dem manifesto commitment for several years, but what brought it to the fore for me was my work with the cross-party commission on serious youth violence. There was clear evidence coming out of it that the more exposure [young people] had to the illicit drugs market, the more likely they were to be exposed to serious violence or know people who were.

“With resources stretched as well, police don’t want to be diverted into activity on cannabis. If you can regulate and make sure the quality is much safer, it removes the need for police to be looking out for that.”


Legalisation has growing support among MPs. Several Tories now privately say they believe the idea is gaining ground. Benita cited comments from former Metropolitan police chief Bernard Hogan-Howe last year, in which he called for an “urgent review” of Britain’s cannabis laws. He said the US had shown how changes could be made in a safe way.


“I’ve not seen clear evidence to say change the law now,” he said. “But I have seen clear evidence to say let’s review it, in a time-limited way, not a kicking-into-the-long-grass way. We need to get on with it. We’re lucky – we’re not the pioneers and we can learn from others’ mistakes. The evidence is out there and it shouldn’t be ignored.”


Benita also called for a “youth happy hour” to tackle youth crime and violence. It would see venues across London lay on activities for them between 4pm and 6pm.

“We know there is a problematic time when young people are particularly vulnerable to getting involved in criminal activity or serious violence – that’s as they leave school,” she said.

“I don’t want to be a mayor that says, ‘I’d do this if I had the resources’. The message I’m getting is that there are organisations that have the venues and volunteers. There are a lot of public buildings across London that lie empty.”



Police seize 195 cannabis plants from ‘sophisticated’ West End factory in the nick of time



Police seize 195 cannabis plants from ‘sophisticated’ West End factory in the nick of time


More than half of the crop had been harvested




Cannabis plants worth over £180,000 were seized in Leicester’s West End shortly before the drugs hit the streets.

Officers arrested two illegal immigrants – who were working as gardeners at the site – during a police raid at the converted premises in Celt Street on Friday July 12.

Elizabeth Dodds, prosecuting told Leicester Crown Court that 195 cannabis plants were found, of which 103 had already been harvested and were drying out, prior to being taken away.

She said 92 other plants were yet to be cropped at the “sophisticated set up,” equipped with time-controlled ventilation, lighting and water pumps.

The electricity meter had been by-passed.



Miss Dodds said the potential street value of the all the illegal plants was estimated at about £186,000.

Yiber Dervishi, 29, and Erblin Duraku, 26, both admitted cannabis production, in their capacity as gardeners.

What the judge said
Judge Nicholas Dean QC said: “No doubt it’s true you both came here searching for a better life intending to send money back to your families in Albania.

“It is, of course, a sadness that people who choose, as you did, to enter the country unlawfully can then find themselves being exploited by those who may have assisted them in getting to this country.

“Whilst you were exploited, you weren’t trafficked and you ended up acting as gardeners in a cannabis factory, which offers you some mitigation but isn’t a defence.


“You did it knowing it was unlawful and were assisting in a relatively large scale commercial cannabis production operation.

“You’re both in your 20’s and have no convictions recorded against you.

“On your release you may be on licence, or it may be you’re deported but that’s a matter for the Home Office and not the court.”

Mitigation for the gardeners
Tim Starkey, mitigating for Duraku, said: “He’s described a difficult financial situation for his family in Albania.

“He was supporting his parents and disabled brother.

“His father had undergone a spinal operation.


“He came to the UK to seek a better life so he’d be able to send money back home.”

Amar Mehta, for Dervishi, said: “It’s a similar story, all too familiar to this court.

“His involvement was a lesser role and the Crown accepts that.

“He would voluntarily submit to deportation at the end of the sentence.”

The sentence
Dervishi and Duraku, both of no fixed address, were each jailed for nine months.




David Lammy Blasts ‘Pot-Smoking Stonehead’ Cameron For Not Legalising Marijuana



David Lammy Blasts ‘Pot-Smoking Stonehead’ Cameron For Not Legalising Marijuana


Vid On Link


David Lammy says there is a “hypocrisy” when ‘privileged’ politicians confess to smoking marijuana but then do nothing about it.

Lammy, himself, confesses to having smoked marijuana himself.


He said: “I first came across marijuana, back in the day, in Tottenham.

“I was 12 at the time and experienced smoking a joint.

“That was the reality, I think, of inner city life in those days.”


But he added: “I’ve recently called for the regulation and legalisation of marijuana because I think that we’ve lost the war on drugs.


“I’m hugely worried about working-class kids, up and down the country, who end up with criminal records as a result of their marijuana use.”

Lammy said: “There are white kids and black kids, working-class, who haven’t got the privilege of David Cameron to take a joint.


“This big confession that David Cameron made – isn’t it time that we actually did something about it?

“Regulating and legalising cannabis.”


He explained how politicians confessing to drug use but doing ‘nothing’ about it isn’t new.

Bill Clinton said he “didn’t inhale” in 1992.


Vid On Link



Cannabis Strains That Are Unexpectedly Similar



Cannabis Strains That Are Unexpectedly Similar

Cannabis strains are made up of cannabinoids (like THC and CBD) as well as terpenes, which are aromatic compounds that give each flower its unique aroma. We’re constantly learning more about these terpenes and how they impact the overall experience of consuming cannabis.


Many Graphics on link with article in full




‘CBD lubricant is a bestseller’: cannabis oil products are booming – but does the science stack up?



‘CBD lubricant is a bestseller’: cannabis oil products are booming – but does the science stack up?


It’s been hailed as a wonder ingredient, added to everything from ice-cream to hummus. But is CBD more than just a wellness trend?

• Plus, high-street products put to the test




ice-cream image


ast month, Lisa Jenkins went for a walk alone around her local park for an hour, the first time she had done so unaided for 13 months. Jenkins was diagnosed with cerebral palsy at the age of three. Now 46, she struggles with vertigo and dizziness, as well as muscle spasms and poor mobility. An Access to Work grant means that she can get a taxi to and from her job in advertising, but for the last three months she hasn’t needed one. The difference? She believes, a few drops of grassy-tasting oil under the tongue each morning.

“I have been using a 5% CBD oil for six months,” she says. “I previously took Duloxetine [an antidepressant medication also used to treat nerve pain] which was initially helpful, but my muscle-freezing episodes came back and I stopped taking it. I was also prescribed Valium, but you can’t take that during the working day.” A friend suggested she try the legal cannabis derivative. She has since been taking it every morning before work, using more during the day if her muscles become tight. “Within an hour of taking those first three drops, my muscles relax,” she says. “The stress in my head calms down. The longer I take it, the better things seem to be.”


Jenkins is one of an estimated 1.3 million UK consumers who spend a total of £300m a year on cannabidiol (CBD) products. The oil contains one of the non-psychoactive chemicals found in the hemp plant – not the illegal mind-altering THC (tetrahydrocannabinol) that gets you high – and has been on the shelves of specialist health food shops and hemp “dispensaries” since 1998. It’s 21 years since the British government first issued a licence for a cannabis extract to be developed for use in clinical trials.


But in the last few years, it has leapt into the mainstream, acquiring the ubiquity of vitamin C and the social status of something much sexier. Most commonly consumed as an oil dropped under the tongue, CBD is also available as gummy sweets, capsules, body salves and e-liquids to vape. A CBD gold rush has led to an explosion of infused products, everything from soft drinks, tea and coffee to ice-cream, toothpaste and shampoo. You can get vaginal suppositories containing CBD (“weed tampons”) that are said to help with pelvic pain; CBD-infused deodorants and sexual lubricant (said to promote relaxation and increase blood flow); even CBD hummus, perhaps to snack on after your lubricated endeavours.


For CBD evangelists, it seems there is no health problem it can’t help – from chronic pain, depression, anxiety and skin conditions to insomnia. Many report that CBD improves concentration, memory and general mood, as well as reducing stress levels. But the products can’t legally make such claims; in the UK, CBD can be sold and advertised only as a generic food supplement. “We never use any medical terminology,” says Johan Obel, director of popular online CBD retailer the Drug Store, standing in front of a huge, gold-framed artwork of a nerve cell in its central London store. “If people come in asking for advice on a specific issue, we tell them to do their own research.” (He adds that their sexual lubricant is “by far one of our bestsellers”.)


The boom in CBD-infused products on the high street is reminiscent of short-lived fads of recent years, such as our brief fixation with chia seeds, turmeric (rendering lattes highlighter-yellow) or spirulina. Only, CBD does not seem to be going anywhere. On a recent walk through London I visited a cafe serving camomile and CBD lattes, passed a yoga studio advertising CBD classes, and a bar serving CBD-infused cocktails. The CBD acronym, with its suggestion of something illicit, is catnip to anxious consumers in need of something they can’t quite put their finger on.


“Most years there is a golden product – a ‘Holy cow, can you believe how much of this we’re selling?’ thing”, says Al Overton, buying director at Planet Organic. “There was the year of quinoa, the year of manuka honey, the year of the goji berry. Now it’s CBD. We have been selling CBD products in our supplement section for just over two years, and it’s been our fastest-growing product in that time. The majority of interested customers are female – especially those who feel that conventional pharmaceuticals aren’t working for them.” He thinks it’s too soon to tell how much of a fixture “infused” foods and drinks will become. “We see oils and capsules as more of a sophisticated and long-lasting trend, but it is early days with the ‘edibles’.”


I have been using CBD oil on and off for two years myself, finances permitting. It’s expensive: a bottle of 1,000mg (10%) CBD oil from Love Hemp, costing £49.99, lasts three weeks on average. I started because I wanted something to help with crippling period pain and associated symptoms, including anxiety. I love the taste; a bitter, herbaceous blast, like a joint dipped in strong extra-virgin olive oil. More importantly, when I take CBD regularly I notice that, when the dreaded week of cramping and gut chaos arrives, my perception of the pain shifts; I am aware of the sensations and their cause, but am less agitated by them. It feels as if the message of pain is being delivered in a different language. But does the science back me up?


Between 2002 and 2012 there were nine published studies on the use of CBD for the treatment of pain. By 2017, there had been 30. Almost all have shown potential benefits. However, with their small participant numbers, along with the fact that those participants are mostly rats, it is hard to make reliable claims about the human response. “Very few of the claims for CBD’s effects have actually been, or are being, tested,” says Dr Sagnik Bhattacharyya, of King’s College London’s (KCL) psychiatry, psychology and neuroscience unit. Scientists there have been investigating whether large doses of CBD could help treat severe mental health problems. “We have carried out a couple of studies where we show that a single 600mg dose of cannabidiol can normalise brain function in key regions we know are abnormal in people with psychosis,” he says. KCL now has funding to carry out a large-scale trial to test whether CBD could be useful in treating young people at high risk for developing psychosis. If successful, its new trial will provide “definitive proof” of CBD’s efficacy as an antipsychotic treatment, and pave the way for clinical use.


Meanwhile, Great Ormond Street hospital (GOSH) has published research showing that CBD has potential as a treatment for epilepsy, particularly for children with the severe, drug-resistant form known as Dravet syndrome. The study showed that CBD reduced seizures by nearly 40% for the 120 children who took part in the trial. Prof Helen Cross, consultant in paediatric neurology at GOSH, said: “The results of this study are significant, and provide us with firm evidence of the effectiveness of cannabidiol. This drug could make a considerable difference to children who are living with Dravet syndrome and endure debilitating seizures.”

CBD has also been shown to be helpful for decreasing the myriad symptoms of anxiety. In 2011, scientists from Brazil conducted a trial with people with social anxiety disorder. Participants were split into two groups; one received a single 600mg dose of CBD, the other a placebo. All subjects completed a simulated public-speaking test which involved choosing a topic from a pre-selected list on which to deliver a speech, directed at a television camera as if addressing a large audience. Those who received the CBD dose before the task experienced considerably reduced anxiety levels compared with the placebo group. Preliminary evidence from another trial, completed this year by scientists at the University of Colorado, also suggests that CBD may be helpful to those who struggle with anxiety-related sleep disturbances.

But there is currently little robust evidence to support the claims CBD users make for the oils, coffees and hummus available on the high street. So, if over a million people are finding these work, are we witnessing a global placebo effect?




The doses used in clinical trials tend to be much higher than you can buy commercially. “It’s usually between 600-1500mg, either as a one-off or repeated dose,” says Dr Chandni Hindocha, a research fellow with University College London’s clinical psychopharmacology unit, and part of a team researching whether CBD can help treat nicotine and other addictions (the results are promising so far). Hindocha emphasises the need for more research into dosing ranges. “There are no observational studies about the lower-dose products people are taking right now. We have no idea how much they’re taking and why they’re taking it.”

In the clinical trials Hindocha has worked on, most participants cannot differentiate between a 100mg dose of CBD and a placebo. “If most people are getting something like 50mg of CBD in a bottle, we need to think about what is going on,” she says. In her opinion one-off doses of CBD in popular edibles are unlikely to have any effect. “We know that the beneficial effects of CBD usually come from building up levels of it in the body,” she explains, but this is with the high trial doses. “There is currently no evidence to show what regular low doses, like 30 or 40mg a day, are doing.”


But what about the vast amount of anecdotal evidence for its efficacy, particularly in helping with chronic pain? Dee Montague, a press officer from Newport, Wales, was diagnosed with endometriosis in 2018, 18 years after first going to the doctor. The impact on her life has been striking. “I played roller derby for eight years but had to quit due to the pain and fatigue. I am completely exhausted by the time I get home from work and can barely function.”


She finds that CBD helps. In 2018, she began to experiment with an oil. “It took a week of regular doses to make any difference,” she says, but she was pleasantly surprised. “I found my cramps were far less intense. My sleep improved slightly, which made a real difference to my quality of life.” She then switched to a skin balm, because “the guidance is to avoid taking CBD oils within two hours of other prescribed medication” and she relies on daily medication for asthma. Montague has now been using a CBD-rich skin balm for a year, applying it to her stomach and pain spots on her legs every morning and night. The 100g jar she buys contains 1,000mg of CBD; Montague admits it is hard to know exactly how much CBD she is using each time, and does not view it as “a cure or painkiller, as such”. But the side-effects are nonexistent compared with opiates, she says. “ I feel far more in control of my pain and day-to-day life.”

CBD works by affecting the function of our endocannabinoid system (ECS). Made up of neurons (nerve cells), endocannabinoids (cannabis-like substances the body makes naturally) and cannabinoid receptors, the ECS is responsible for regulating the body’s systems to maintain homeostasis: keeping our internal temperature, blood sugar and pH levels balanced, along with the amount of water in the body. It tells the body when to start sweating (to cool down) and when to stop. Everything from chronic pain to migraines and epileptic seizures have been linked to ECS deficiency.

It is thought that when we introduce a new cannabinoid into the body, such as CBD, it binds with these receptors and, like a molecular power-up, increases the amount of natural cannabinoids in the body. CBD has also been shown to bind with receptors for serotonin (our feelgood molecule) and GABA (the molecule that calms the nervous system), increasing the amount available to the body – offering a potential explanation for CBD’s reported calming effects.

I asked Hindocha whether stories such as Montague’s suggest that such small doses could be having an impact? “It is very interesting,” she says, “because there is an argument that low doses of CBD could potentially affect inflammation in the body.” One complicating factor is metabolism. “When someone takes CBD oil, much of it will be broken down by the liver,” Hindocha explains. “Without knowing about their metabolism, we have no idea how much CBD they’re really absorbing.”




Before you can consider how much you’re absorbing, you need to know how much you’re taking in the first place: this year a major study by the Centre for Medicinal Cannabis found that 38% of CBD oils contain less than half the amount of CBD stated on the label. Almost half (45%) of the products contained more than 0.2% of THC (the Home Office’s legal threshold) and, therefore, were technically illegal in the UK.


Browse the CBD shelf in your local health shop and you’ll find a huge variation of strengths on offer; but a higher CBD content means a higher price. Holland & Barrett sells a 10ml bottle of oil by Jacob Hooy containing 5% CBD for £29.99; Boots stocks 10ml bottles by Dragonfly containing 11.1% CBD for £70. One of the strongest products available is by Love Hemp: a 10ml bottle with 40% CBD, for £259.99. Love Hemp suggests a maximum daily dose of 200mg; while it is thought impossible to overdose on CBD, most producers offer guidance on dosing. I notice that none of the infused products carry warnings about maximum doses, age limits, or driving.


Hemp can be legally grown in the UK with a government licence, but is an incredibly small sector. It is estimated that only 810 hectares (2,000 acres) of hemp are currently cultivated in the UK’s 42m acres of agricultural land. When I visited a couple of rough-and-ready CBD outlets in London which, as well as oils, sold whole hemp flowers in clear plastic bags, it made me nervous about where it came from. I was routinely assured the flowers contained less than the legal 0.2% of THC. But how can a layperson, without access to a lab and a scientist to test it, really know?


The nice man running one of my local CBD shops – a modest outfit selling oils, e-liquids, balms and bongs – offered me tea and lots of convincing chat, but agreed that dosing essentially comes down to experimenting. The smell of his shop instantly, rather thrillingly, transported me to the top of the multistorey car park in Bishop’s Stortford, the locus of my teenage experimentation with marijuana. Perhaps that whiff of transgression contributes to CBD’s seductiveness? Even if we know it won’t get us high, it’s wellness with an edge.

The Drug Store’s Obel tells me that nearly all the CBD products in the UK originate from the same wholesalers; the extraction equipment is too expensive for smaller companies. “It takes a long time to figure out how to do it properly – only a few people actually have the knowledge,” he explains. In most cases, producers simply add the extract to their carrier oil of choice and put a new label on it.


Obel says the majority of his customers are women aged 40 and above. The audience for a recent in-store event, a panel discussion on the impact of stress, was 80% female. “From what we have seen, women want to self-educate and be responsible for their own health. They want to seek more options than those offered by traditional medicine,” he says. He does not believe the boom in CBD-infused high-street products like chocolate, tea and hummus will last: “We believe everyday products with CBD added will fade away. Products in which CBD is the actual active ingredient, or where CBD serves a specific purpose in supplements or cosmetics – those will most likely remain.”




That we currently have no idea of CBD’s full potential is at once incredibly exciting and frustrating. Without more dedicated research, the commercial market will remain something of a wild west. Meanwhile, people will continue to inform themselves, spending their money on products with, it seems, woolly efficacy. The costs will remain prohibitive to many. Meanwhile brands will continue merrily infusing their teas and ice-creams with nominal amounts of CBD, knowing that people will pay extra for the buzz cannabis brings.


I am now thinking more carefully about my own experimentation. Unless I pay close to £300 on a regular basis, for the highest strength of CBD oils commercially available – the only products that come close to what is being clinically tested – it strikes me that I may be experiencing a placebo effect. Then again, with the research in its infancy, I might not. So I will finish the bottle I have. Beyond that, the question is: how much am I willing to pay for a maybe?


A touch of grass: high-street CBD, taste-tested
Buddha Teas CBD Matcha Green Tea Blend (18 bags), £16.99

Buddha Teas CBD Matcha Green Tea Blend
They say “Our innovative process ensures that the CBD in our tea bags actually ends up in your tea.”

CBD count 5mg per bag

Our verdict “The taste is very subtle and the bags can rip, but I was surprised at how easily I fell (and stayed) asleep – I’m normally a very light sleeper.”

Themptation Hemp Chocolate Spreadables CBD vanilla spread, 165g, £5.05

Themptation Hemp Chocolate Spreadables CBD vanilla spread
They say “More seeds than sugar, more hemp than any other ingredient, packed with 10mg of organic CBD oil and vanilla.”

CBD count 10mg

Our verdict “This is so delicious and wholesome-tasting, it’s hard to separate that feelgood factor from any CBD effect. Definitely moreish; keep away from kids.”

Aussie ‘calm the frizz’ Shampoo, 300ml, £3.99

Aussie ‘calm the frizz’ Shampoo
They say “Our miraculous formula, with Australian hemp seed extract, will tame your mane in next to no time.”

CBD count Some cannabis sativa seed extract.

Our verdict “Foamy and minimally scented, this resulted in noticeably softer, smoother hair. Was that the hemp? I liked it more than other Aussie shampoos.”

Wunder Workshop turmeric x CBD Raw Chocolate Bliss bar , 40g, £6.99

Wunder Workshop turmeric x CBD Raw Chocolate Bliss bar
They say “With cacao from Peru; turmeric from Sri Lanka; and boosted with CBD.”

CBD count 16mg

Our verdict “I liked the taste – definitely got the turmeric – but no obvious relaxing effect.”

Nooro raw, vegan oat CBD bar in Cacao & Coconut, 45g, £2.95

Nooro raw, vegan oat CBD bar in Cacao & Coconut
They say “Our CBD is sourced from a small independent UK grower.”

CBD count 25mg

Our verdict “Pleasant initially, but followed by a soapy aftertaste. Quite sickly.”

BumbleZest ginger, turmeric and CBD shot, 60ml, £3.15

BumbleZest ginger, turmeric and CBD shot
They say “A natural fiery drink with a lemon base, designed to be taken as a health shot on the go.”

CBD count 2.5mg

Our verdict One tester found it “very acidic, quite unpleasant, made me sneeze”. Another loved the fieriness: “I felt energised and set up for the day. Or it could have been my morning swim.”

The Marshmallowist limited edition marshmallows, £15 for a box of six

The Marshmallowist limited edition marshmallows
They say “Crafted from organic CBD-infused mallow whipped to create a super-light texture. Do not exceed two marshmallows per day.”

CBD count 10mg per marshmallow

Our verdict “Great flavours (choose from cocoa, blood orange or grapefruit), very fluffy, not too sweet, these started life on a market stall and still have that premium feel.”

Drink 420 – CBD infused elderflower & lime or wild berry drink; 250ml, £2.29

Drink 420 – CBD infused elderflower & lime or wild berry drink
They say “Water. Zingy fruits. The legal bit from cannabis. Plant extracts. What could be purer?”

CBD count 15mg

Our verdict “Nice: there was something dry and hempy beneath the zing. I felt a bit spaced out – but was it the placebo effect?”

Themptation CBD Hummus, 190g, £4.75

Themptation CBD Hummus
They say “Packs an anti-inflammatory punch with a delicious herby sage taste.”

CBD count 13mg

Our verdict “I liked the grainy texture, but there was a strange aftertaste. I ate half the pot without thinking about it and felt spaced out afterwards – dinner at my mother-in-law’s was a very relaxed affair.”





Gardai seize 117 cannabis plants worth €90,000 after discovering grow house in Co Limerick



Gardai seize 117 cannabis plants worth €90,000 after discovering grow house in Co Limerick


Irish Mirror 


The grow house was located in the garage


Gardai have seized 117 cannabis plants worth €90,000 after discovering a grow house in Co Limerick.

The massive find came as part of a planned search operation of a property in the Cappamore area, led by detective and uniformed officers based in Bruff.

The grow house was located in the garage of the building.




A garda spokesman said: “A total of 117 mature plants were seized in a converted garage unit fitted out with heating, lighting, and irrigation and ventilation systems.

“No arrests have been made to date but Gardaí investigating the case say they are following a definite line of inquiry.

“The search was carried out as part of ongoing operations by Gardaí from the Bruff District targeting the sale and supply of controlled drugs in the Cappamore, Pallasgreen and Murroe areas.”


We’ll be bringing you the very latest on this breaking news story.

For the latest news and breaking news visit .

Get all the big headlines, pictures, analysis, opinion and video on the stories that matter to you.

Follow us on Twitter @IrishMirror – the official Irish Mirror Twitter account – real news in real time.

We’re also on Facebook/irishmirror – your must-see news, features, videos and pictures throughout the day from the Irish Daily Mirror, Irish Sunday Mirror and



Police seize stash of cannabis plants in Revesby



Past in by member Thank you :yep:


Police seize stash of cannabis plants in Revesby


This photograph of the seized cannabis stash was posted on Horncastle Police's Twitter page. EMN-191109-113630001


Investigations are ongoing after a stash of cannabis plants were discovered in Revesby over the weekend.

A Lincolnshire Police spokesman said: “Incident 240 of September 8 refers to a resident reporting a suspected cannabis grow of around 16 plants found behind some bushes in Revesby.

“These plants have been removed by officers.

“Investigations are ongoing and no arrests have been made.”



Your message has been successfully sent.
Oops! Something went wrong.

Get in touch

If you wish to enquire about anything, or just say hi, please fill in the form opposite, or email us on: